HDAC9 and Cognitive impairment: In clinical trials with AD patients, HDAC inhibitors (sodium butyrate, suberoylanilide hydroxamic acid/Vorinostat, Trichostatin A, and valproate) improve memory, decrease cognitive impairments, and reduce endogenous Aβ production [73].